By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: A Silent Disease Becoming a Public Health Emergency Metabolic…
How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency…
Volv Global presented two posters at ATS 2025, in collaboration with Takeda The posters were the result of work to…
Alpha-1 antitrypsin deficiency (AATD) Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition which can cause lung disease in adults…